For example, LCK had synthetic viability effect with SETBP1. A enhancement of cell growth or viability were identified when LCK was knocked down by shRNA (P = 0.02, one-sided Wilcoxon rank-sum test; Fig. 6H) or CRISPR1 (P = 0.04, one-sided Wilcoxon rank-sum test; Fig. 6I) in endometrium tissue with mutations of SETBP1. In addition, SETBP1 mutated endometrium cancer cells were resistant to Dasatinib, a targeted drug of LCK in CTRP (P = 0.02, one-sided Wilcoxon rank-sum test; Fig. 6J) and GDCS2 (P = 0.04, one-sided Wilcoxon rank-sum test; Fig. 6K). This evidence concerns the gene SETBP1 and endometrial cancer.